GLP1R and inflammatory bowel disease: Reassuringly, recent studies have demonstrated that GLP-1R agonist therapy is not associated with increased risk of serious gastrointestinal adverse events, including ileus, intestinal obstruction, IBD-related hospitalization, corticosteroid use, medication escalation, or IBD-related surgery [131,173,174].